GlassScriptPhysician profile
Patricia Rivera
NPI 1134450232
$9,569.19
in general payments reported to CMS, 2019-2025
27 companies · $3,954 in 2025
The $3,954 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,175 · 2022: $968 · 2023: $1,068 · 2024: $1,404 · 2025: $3,954.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,886 · Travel and Lodging: $1,520 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,886.14 |
| Travel and Lodging | $1,519.66 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,783.99 | 2025 | Xience V, Perclose Proglide, Supera |
| Medtronic, INC. | $1,604.57 | 2021-2025 | Aurora Ev-Icd Mri Surescan, Cobalt Dr Mri Surescan, Linq II |
| Biotronik INC. | $1,470.11 | 2021-2025 | Biomonitor, Acticor 7 Vr-T Dx, Rivacor 7 Dr-T |
| E.R. Squibb & Sons, L.L.C. | $818.14 | 2021-2025 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $728.00 | 2021-2024 | Xarelto |
| Lilly USA, LLC | $565.27 | 2023-2025 | Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $483.69 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $307.07 | 2021-2025 | Verquvo |
| Novo Nordisk INC | $286.05 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $247.84 | 2021-2024 | Farxiga |
| Cvrx, INC. | $212.76 | 2025 | Barostim Neo System |
| Cardiovascular Systems INC. | $163.38 | 2021-2022 | |
| Edwards Lifesciences Corporation | $136.47 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $129.35 | 2021-2025 | Lifevest |
| Inspiremd LTD | $112.16 | 2025 | Cguard Prime Carotid Stent System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $109.79 | 2021-2025 | |
| Abiomed | $86.00 | 2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $79.70 | 2025 | |
| Chiesi USA, INC. | $66.60 | 2021-2023 | Cleviprex |
| Amarin Pharma, INC. | $41.98 | 2021-2022 | |
| Boston Scientific Corporation | $36.98 | 2021-2022 | |
| Lexicon Pharmaceuticals, INC. | $24.23 | 2023 | Inpefa |
| Sanofi-Aventis U.S. LLC | $20.35 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.75 | 2023 | Jardiance |
| Arbor Pharmaceuticals, INC. | $13.53 | 2021 | |
| Preventice Services, LLC | $13.41 | 2021 | |
| Xeris Pharmaceuticals, INC. | $12.02 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patricia Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.